Lavipharm (LAVI.AT) Stock Price
Lavipharm Price
Revenue at Lavipharm has contracted by 6.6% per year over the past 19 years to 62.58 M EUR. Earnings per share have declined at 3.1% per year over the last 19 years. For Lavipharm, the net margin of 9.6% is up versus 4.3% a few years ago. At today's price the dividend yield works out to roughly 1.28%. The payout ratio is around 56% of earnings.
Lavipharm stock price
Lavipharm business model & stock analysis
Frequently asked questions about Lavipharm
The expected revenue of Lavipharm is 81.95 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Lavipharm is 6.75 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Lavipharm is currently 39.08. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lavipharm stock.
The price-to-sales ratio (P/S) of Lavipharm is currently 3.22. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Lavipharm stock.
The Eulerpool Quality Score for Lavipharm is 7/10.
The ISIN of Lavipharm is GRS246003008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Lavipharm is A3DSHM. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Lavipharm is LAVI.AT. The ticker symbol is used to trade Lavipharm shares on the stock exchange.
Lavipharm stock
Lavipharm Peer Group
Lavipharm FIGI
All fundamentals and in-depth analysis of Lavipharm
Our stock analysis for Lavipharm stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lavipharm. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.